

Figure S1. Proliferation of hASCs with PLTMax. (A) Dose-dependent viability of hASCs with PLTMax. Cells were incubated with the indicated concentrations of PLTMax for 48 h. Cell viability was examined using CCK-8 assays and measuring the optical density at 450 nm. Data are expressed as the mean \pm SD of three experiments. * P <0.05; ** P <0.01 vs. no addition. (B) Effect of trypsin treatment of PLTMax on hASC proliferation. PLTMax was incubated with trypsin (1 mg/ml) at 37°C for 30 min, and the reaction was stopped by the addition of TI (at a final concentration of 2 mg/ml). The cells were cultured with or without 3% PLTMax, 3% trypsin-treated PLTMax and 3% PLTMax plus TI (60 μ g/ml), for 48 h, and CCK-8 assays were performed. Data are expressed as the mean \pm SD (n=4). * P <0.05 vs. PLTMax treatment. hASCs, human adipose-derived stem cells; CCK-8, Cell Counting Kit-8; PLT, platelet lysate; TI, trypsin inhibitor.




Figure S2. Effect of PDGF-BB on the proliferation of hASCs. Cells were cultured in DMEM with or without the indicated concentrations of PDGF-BB for 48 h. Cell viability was measured using Cell Counting Kit-8 assays. Data are shown as the mean \pm SD (n=3). **P<0.01 vs. no addition. hASCs, human adipose-derived stem cells; PDGF, platelet-derived growth factor.




Figure S3. Synergistic effect of EGF on the PDGF-dependent viability of hASCs. (A) hASCs were incubated with PDGF (1, 5 and 20 ng/ml), EGF (1 and 5 ng/ml) and PDGF (20 ng/ml)/EGF (1 ng/ml) for 48 h. Cell viability was then assayed using Cell Counting Kit-8 assays. The cell viability was examined by optical absorbance at 450 nm using a multi-well plate reader (EnSpire 2300 Multilabel Reader; PerkinElmer, Inc.). Data are presented as the mean \pm SD (n=3). *P<0.05 vs. no addition. (B) Pharmacological inhibition of hASC proliferation when cultured with PDGF (20 ng/ml)/EGF (1 ng/ml). The cells were cultured with or without PD153035 (10 μ M; Cayman Chemical Company; cat. no. 18080), imatinib (5 μ M) and PD153035 plus imatinib. Data are expressed as the mean \pm SD (n=4). **P<0.01 vs. no inhibitor. hASCs, human adipose-derived stem cells; PDGF, platelet-derived growth factor; EGF, epidermal growth factor.

